Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides novel methods for delivering cells, particularly modified cells to the central nervous system (CNS). The purpose of this invention is to present a method that provides sustained delivery of a molecule to the central nervous system, thereby increasing the bioavailability of the molecule and lengthening the possible duration of treatment.
18 Citations
51 Claims
-
1-20. -20. (canceled)
- 21. A composition for the treatment of a subject affected by or susceptible to being affected by a CNS disorder, wherein the composition comprises a population of human cells enriched in human cells that can express human CD34, wherein at least of portion of the cells comprises a nucleic acid of interest, and wherein the composition comprises the human cells in an amount sufficient to migrate to the CNS of a human subject and express the nucleic acid of interest in the CNS of the human subject when intravenously administered to the subject.
- 37. A method of treating a subject affected by or susceptible to being affected by a CNS disorder, wherein the method comprises administering to the subject a composition comprising a population of human cells enriched in human cells that can express human CD34, wherein at least of portion of the cells comprises a nucleic acid of interest, and wherein the composition is administered to the subject in an amount sufficient to migrate to the CNS of a human subject and express the nucleic acid of interest in the CNS of the human subject when intravenously administered to the subject.
Specification